CA2414352A1 - Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies - Google Patents

Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies Download PDF

Info

Publication number
CA2414352A1
CA2414352A1 CA002414352A CA2414352A CA2414352A1 CA 2414352 A1 CA2414352 A1 CA 2414352A1 CA 002414352 A CA002414352 A CA 002414352A CA 2414352 A CA2414352 A CA 2414352A CA 2414352 A1 CA2414352 A1 CA 2414352A1
Authority
CA
Canada
Prior art keywords
treating
neuropathies
peripheral
derivative
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002414352A
Other languages
French (fr)
Inventor
Ralph E. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2414352A1 publication Critical patent/CA2414352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A method of treating a patient suffering from peripheral vascular disease, peripheral neuropathies, or autonomic neuropathies by administering a cGMP PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor ma y be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.< /SDOAB>

Description

METHOD

Claims (7)

What I claim is:
1. A method of treating the disease of a type selected from peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies, comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
2. A method of treating a disease according to claim 1 wherein said disease is selected from the group consisting of Raynaud's Phenomenon, CREST syndrome, erythromatosis, rheumatoid diseases and diabetic retinopathies.
3. A method of treating onychiomycosis comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
4. A method of treating a patient suffering from diabetic foot ulcers which comprises treating said patient with an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
5. A method of preventing the formation of foot ulcers in a patient suffering from the disease diabetes, the method comprising administering to said patient an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
6. A method of manufacturing a diabetic foot ulcer therapeutic comprising providing an effective ingredient selected from the group consisting of a cGMP
PDES
inhibitor, a derivative thereof, and a salt thereof and combining said effective ingredient with a suitable carrier for administration to a patient.
7. A method according to claim 4 or 5, wherein the cGMP PDE 5 inhibitor is sildenafil.
CA002414352A 2000-06-30 2001-06-29 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies Abandoned CA2414352A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21506500P 2000-06-30 2000-06-30
US60/215,065 2000-06-30
US21902900P 2000-07-18 2000-07-18
US60/219,029 2000-07-18
PCT/US2001/041202 WO2002002118A1 (en) 2000-06-30 2001-06-29 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies

Publications (1)

Publication Number Publication Date
CA2414352A1 true CA2414352A1 (en) 2002-01-10

Family

ID=26909649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002414352A Abandoned CA2414352A1 (en) 2000-06-30 2001-06-29 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies

Country Status (13)

Country Link
EP (1) EP1303279A1 (en)
JP (1) JP2004511433A (en)
KR (1) KR20030047907A (en)
CN (1) CN1440287A (en)
AU (1) AU2001279275A1 (en)
BR (1) BR0112100A (en)
CA (1) CA2414352A1 (en)
HU (1) HUP0301451A3 (en)
IL (1) IL153426A0 (en)
MX (1) MXPA03000033A (en)
NZ (1) NZ523108A (en)
PL (1) PL365565A1 (en)
WO (1) WO2002002118A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
CA2519357A1 (en) * 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
FR2877013A1 (en) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA
EP1838319B1 (en) * 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
JP2004511433A (en) 2004-04-15
WO2002002118A1 (en) 2002-01-10
KR20030047907A (en) 2003-06-18
AU2001279275A1 (en) 2002-01-14
BR0112100A (en) 2003-05-20
MXPA03000033A (en) 2003-09-25
HUP0301451A3 (en) 2004-10-28
NZ523108A (en) 2005-04-29
HUP0301451A2 (en) 2003-09-29
PL365565A1 (en) 2005-01-10
IL153426A0 (en) 2003-07-06
CN1440287A (en) 2003-09-03
EP1303279A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
CN101287457B (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
JP2004507496A5 (en)
JP2002506023A (en) Methods and compositions for the treatment and prevention of mucositis
KR20070032619A (en) Combination Therapeutics of Iloprost for the Treatment of Pulmonary Hypertension
JP2002523370A5 (en)
JP2002528502A5 (en)
CA2563058A1 (en) Supportive treatment of liver disease
CA2559239A1 (en) Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
CA2414352A1 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
JP2005525329A5 (en)
RU2543635C2 (en) Method and pharmaceutical compositions for treating postprandial hyperglycemia accompanying type ii diabetes mellitus by administering through oral mucosa
JP2002534477A (en) New use of melagatran
JPH01261334A (en) Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof
AU2002220960B2 (en) Regeneration of blood vessels
CA2493208A1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
CA2590224A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
AU2002220960A1 (en) Regeneration of blood vessels
MXPA02009603A (en) Divided dose therapies with vascular damaging activity.
MD1568G2 (en) Method of treatment of the burn disease in the burn shock period
RU2003106417A (en) APPLICATION OF A VITAMIN COMBINATION FOR TREATMENT OF PRIMARY HEAD PAIN
JPH0959149A (en) Antiphlogistic and analgesic composition

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued